Warning Letter — Guangdong Bangze Medicine Co., Ltd.
The FDA issued a Warning Letter to Guangdong Bangze Medicine Co., Ltd. following an evaluation by the Center for Drug Evaluation and Research (CDER). The specific violations were not detailed in the provided excerpt, but the letter originated from the Office of Manufacturing Quality.
This affects Guangdong Bangze Medicine Co., Ltd., its global supply chain partners, and regulatory compliance teams overseeing drug products manufactured by this entity.
A Warning Letter from CDER typically indicates significant deviations from Current Good Manufacturing Practice (CGMP). For an international firm, this may result in an Import Alert, potentially blocking the entry of their products into the United States market until corrective actions are verified by the FDA.
Firms should verify that all contract manufacturing partners are in compliance with CGMP standards and review recent FDA inspectional histories for international suppliers. Quality units should audit manufacturing documentation and facility controls to ensure they meet CDER expectations for exported drug products.
FDA Warning Letter issued to: Guangdong Bangze Medicine Co., Ltd.. 10/26/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangdong-bangze-medicine-co-ltd-734509-10262026
Open in openFDA / FDA.gov